Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Eli Lilly
(NY:
LLY
)
207.41
USD
+0.94 (+0.46%)
Streaming Delayed Price
Updated: 10:51 AM EST, Mar 2, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press releases about Eli Lilly
< Previous
1
2
3
4
5
6
7
8
9
...
89
90
Next >
U.S. Government to Purchase Minimum of 100,000 Doses of Etesevimab and Bamlanivimab Neutralizing Antibody Therapy
February 26, 2021
From
GlobeNewswire News Releases
Lilly announces additional doses of neutralizing antibody therapy purchased by U.S. government to treat COVID-19
February 26, 2021
The U.S. government has agreed to purchase a minimum of 100,000 doses of bamlanivimab (LY-CoV555) 700 mg and etesevimab (LY-CoV016) 1400 mg together, Eli Lilly and Company (NYSE: LLY) announced....
From
PR Newswire
Welldoc and Lilly collaborate to integrate BlueStar® app capabilities into Lilly's connected insulin solutions
February 25, 2021
Welldoc, Inc., and Eli Lilly and Company (NYSE: LLY) announced today a collaboration and licensing agreement to integrate Welldoc's software into Lilly's connected insulin solutions, currently in...
From
PR Newswire
Lilly to Participate in Cowen Health Care Conference
February 24, 2021
Eli Lilly and Company (NYSE: LLY) will participate in the Cowen and Company 41st Annual Health Care Conference on Thursday, March 4, 2021. Daniel Skovronsky, M.D., Ph.D., Lilly's Chief Scientific...
From
PR Newswire
Lilly and Rigel Enter Strategic Collaboration to Develop RIPK1 Inhibitors for the Potential Treatment of Immunological and Neurodegenerative Diseases
February 18, 2021
- Lilly will obtain an exclusive worldwide license to Rigel's RIPK1 inhibitors, including Rigel's Phase 2-ready molecule R552, in all indications
From
PR Newswire
Tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes in two phase 3 trials from Lilly's SURPASS program
February 17, 2021
In the 52-week SURPASS-3 study - the longest in the program to date - the highest dose of tirzepatide reduced A1C by 2.37 percent and body weight by 12.9 kg (28.4 lb., 13.9 percent)
From
PR Newswire
Kimberly H. Johnson Elected to Lilly Board of Directors
February 17, 2021
The board of directors of Eli Lilly and Company (NYSE: LLY) has elected Kimberly H. Johnson as a new member, effective February 16, 2021. As a member of Lilly's board, she will serve on both the...
From
PR Newswire
Lilly To Participate in SVB Leerink Global Healthcare Conference
February 11, 2021
Eli Lilly and Company (NYSE:LLY) will participate in the 10th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 24, 2021. Ilya Yuffa, Lilly senior vice president and president of...
From
PR Newswire
Thinking about trading options or stock in Coca-Cola, Eli Lilly, Baidu, Canopy Growth Corp, or Match Group?
February 10, 2021
InvestorsObserver issues critical PriceWatch Alerts for KO, LLY, BIDU, CGC, and MTCH.
From
PR Newswire
Etesevimab (JS016) Administered with Bamlanivimab Receives FDA Emergency Use Authorization for COVID-19
February 10, 2021
From
GlobeNewswire News Releases
Lilly's bamlanivimab (LY-CoV555) administered with etesevimab (LY-CoV016) receives FDA emergency use authorization for COVID-19
February 09, 2021
- Bamlanivimab and etesevimab administered together authorized for treatment of recently diagnosed, mild to moderate COVID-19 in patients who are high risk for progression to severe COVID-19
From
PR Newswire
Lilly Appoints Anat Ashkenazi Chief Financial Officer
February 09, 2021
Eli Lilly and Company (NYSE: LLY) today announced the appointment of Anat Ashkenazi as senior vice president and chief financial officer. Ms. Ashkenazi, who most recently served in the role of senior...
From
PR Newswire
Lilly Announces Webcast to Provide Alzheimer's Disease Update at AD/PD Conference
February 04, 2021
Eli Lilly and Company (NYSE: LLY) will conduct a webcast on Monday, March 15, 2021 to provide an update on its Alzheimer's disease program and discuss results from the Phase 2 TRAILBLAZER-ALZ study for...
From
PR Newswire
Lilly to Participate in Guggenheim Healthcare Talks 2021 Oncology Day
February 03, 2021
Eli Lilly and Company (NYSE: LLY) will participate in the Guggenheim Healthcare Talks 2021 Oncology Day on Friday, February 12, 2021. Anne White, senior vice president and president, Lilly Oncology,...
From
PR Newswire
Innovent and Lilly Jointly Announce the Approval of TYVYT® (sintilimab injection) by China NMPA in Combination with Pemetrexed and Platinum Chemotherapy as First-Line Therapy for Nonsquamous Non-Small
February 02, 2021
Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic,...
From
PR Newswire
Lilly Partners with Area Health Systems to Help Enable Access to Important Antibody Infusion Therapies for COVID-19 Patients
February 01, 2021
Eli Lilly and Company (NYSE: LLY) has partnered with local health systems to launch dedicated infusion center locations serving central, northern, and now southern Indiana that are intended to provide...
From
PR Newswire
Should you invest in Dillard's, Inovio Pharmaceuticals, Eli Lilly, Nektar Therapeutics, or Carnival Corp?
January 29, 2021
InvestorsObserver issues critical PriceWatch Alerts for DDS, INO, LLY, NKTR, and CCL.
From
PR Newswire
Lilly Reports Strong Fourth-Quarter and Full-Year 2020 Financial Results
January 29, 2021
- Revenue in the fourth quarter of 2020 increased 22 percent, driven by volume growth of 24 percent. Excluding bamlanivimab revenue of $871 million, fourth-quarter 2020 revenue grew 7 percent.
From
PR Newswire
Lilly, Life for a Child and Beyond Type 1 advance partnership to improve diabetes care in resource-limited countries
January 28, 2021
Partnership expands access to care for children and young people with diabetes to approximately 150,000 in 65 countries
From
PR Newswire
Lilly and Asahi Kasei Pharma Announce License Agreement for Chronic Pain Drug Candidate
January 28, 2021
Eli Lilly and Company (NYSE: LLY) and Asahi Kasei Pharma Corporation today announced a license agreement whereby Lilly will acquire the exclusive rights for AK1780 from Asahi Kasei Pharma. AK1780 is an...
From
PR Newswire
Lilly, Vir Biotechnology and GSK Announce First Patient Dosed in Expanded BLAZE-4 Trial Evaluating Bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19
January 27, 2021
From
GlobeNewswire News Releases
Lilly, Vir Biotechnology and GSK announce first patient dosed in expanded BLAZE-4 trial evaluating bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19
January 27, 2021
Eli Lilly and Company (NYSE: LLY), Vir Biotechnology, Inc. (NASDAQ: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced a collaboration to evaluate a combination of two COVID-19 therapies in...
From
PR Newswire
New data show treatment with etesevimab (JS016) and bamlanivimab together reduced risk of COVID-19 hospitalizations and death by 70 percent
January 26, 2021
From
GlobeNewswire News Releases
Thinking about trading options or stock in Eli Lilly, Apple, Moderna, Workhorse Group, or iRobot?
January 26, 2021
InvestorsObserver issues critical PriceWatch Alerts for LLY, AAPL, MRNA, WKHS, and IRBT.
From
PR Newswire
New data show treatment with Lilly's neutralizing antibodies bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016) together reduced risk of COVID-19 hospitalizations and death by 70 percent
January 26, 2021
- BLAZE-1 trial met primary endpoint and key secondary endpoints with high statistical significance
From
PR Newswire
Lilly Completes Acquisition of Prevail Therapeutics
January 22, 2021
Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of Prevail Therapeutics Inc. (NASDAQ: PRVL). The acquisition establishes a new modality for drug discovery...
From
PR Newswire
Lilly's neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 at nursing homes in the BLAZE-2 trial, reducing risk by up to 80 percent for residents
January 21, 2021
Bamlanivimab (LY-CoV555) significantly reduced the risk of contracting symptomatic COVID-19 among residents and staff of long-term care facilities, Eli Lilly and Company (NYSE: LLY) announced. The...
From
PR Newswire
Thinking about trading options or stock in General Motors, Eli Lilly, CarMax, Micron Technology, or Roku?
January 20, 2021
InvestorsObserver issues critical PriceWatch Alerts for GM, LLY, KMX, MU, and ROKU.
From
PR Newswire
Lilly and Merus NV Announce Collaboration to Discover Novel T-Cell Re-Directing Bispecific Antibodies
January 19, 2021
Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Merus N.V. (NASDAQ: MRUS), a clinical-stage oncology company developing multi-specific antibodies,...
From
PR Newswire
Lilly Confirms Date and Conference Call for Fourth-Quarter 2020 Financial Results Announcement
January 15, 2021
Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter and full-year 2020 financial results on Friday, January 29, 2021. Lilly will also conduct a conference call on that day with the...
From
PR Newswire
< Previous
1
2
3
4
5
6
7
8
9
...
89
90
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.